Loading
Latest filing published 15 Sept 2023 for iSpecimen Inc., €12k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Benjamin Bielak, listed as senior executive, appears in our data through filings on iSpecimen Inc. shares, published by SEC (Form 4). The record holds 2 filings, for trades running from 22 June 2022 to 14 September 2023.
Every open-market trade on record is a purchase: 1 purchase worth €12k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant. So far in 2023, the count stands at 1 purchase and no sales.
On 15 September 2023 came the latest disclosure, an open-market purchase for €12k in iSpecimen Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations